Current state of type 2 diabetes management

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• Type 2 diabetes mellitus (T2DM) presents significant public health challenges in the US.
• Despite available treatments and guidelines, T2DM management remains suboptimal.
• Current pharmacotherapies target various organs to control hyperglycemia, with new agents under development.

Purpose of the Study:

• To review current management strategies for T2DM.
• To highlight the role of emerging therapies, including SGLT2 inhibitors and advanced insulin regimens.
• To emphasize the importance of individualized treatment approaches for optimal patient outcomes.

Main Methods:

• Review of existing evidence-based management guidelines for T2DM.
• Discussion of the mechanism of action and clinical application of sodium glucose cotransporter 2 (SGLT2) inhibitors.
• Analysis of principles for initiating and optimizing insulin therapy, including basal-bolus regimens.

Main Results:

• Sodium glucose cotransporter 2 (SGLT2) inhibitors, such as canagliflozin, offer a novel approach by reducing renal glucose reabsorption.
• Despite advances, T2DM progression often necessitates insulin therapy.
• Effective management requires a thorough understanding of monotherapy, combination therapy, and complex insulin regimens.

Conclusions:

• Optimal T2DM management necessitates a comprehensive understanding of pharmacotherapeutic options, including SGLT2 inhibitors and insulin.
• Individualized treatment strategies, considering factors influencing therapeutic choices, are crucial for improving patient outcomes.
• Adherence to evolving management guidelines is essential for addressing the complexities of T2DM care.